ASCO 2021: A Phase 3, Multicenter, Randomized Study Evaluating the Efficacy of TAR-200 in Combination with Cetrelimab Versus Concurrent Chemoradiotherapy in Participants with Muscle-Invasive Urothelial Carcinoma of the Bladder

(UroToday.com) The standard of care for patients with muscle-invasive bladder cancer consists of neoadjuvant chemotherapy and radical cystectomy or chemoradiotherapy. However, radical cystectomy is associated with potential morbidity or mortality from the procedure. TAR-200 is an intravesical drug-delivery system designed for the local continuous release of gemcitabine within the bladder: